Ebola virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins

Till Koch; Monika Rottstegge; Paula Ruibal; Sergio Gomez-Medina; Emily V. Nelson; Beatriz Escudero-Pérez; Matthias Pillny; My Linh Ly; Fara Raymond Koundouno; Joseph Akoi Bore; N’Faly Magassouba; Christine Dahlke; Stephan Günther; Miles W. Carroll; Marylyn M. Addo; César Muñoz-Fontela

doi:10.3390/v12090915

Ebola virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins

Till Koch, Monika Rottstegge, Paula Ruibal, Sergio Gomez-Medina, Emily V. Nelson, Beatriz Escudero-Pérez, Matthias Pillny, My Linh Ly, Fara Raymond Koundouno, Joseph Akoi Bore, N’Faly Magassouba, Christine Dahlke, Stephan Günther, Miles W. Carroll, Marylyn M. Addo, César Muñoz-Fontela^*

^*Corresponding author for this work

Research & Development Institute Divisional Office

Research output: Contribution to journal › Article › peer-review

13 Citations (Scopus)

Abstract

The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates.

Original language	English
Article number	915
Journal	Viruses
Volume	12
Issue number	9
DOIs	https://doi.org/10.3390/v12090915
Publication status	Published - Sept 2020

Bibliographical note

Publisher Copyright:
© 2020 by the authors. Licensee MDPI, Basel, Switzerland.

Keywords

Antibodies
Ebola virus
Immune memory
VSV
Vaccine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3390/v12090915

Cite this

Koch, T., Rottstegge, M., Ruibal, P., Gomez-Medina, S., Nelson, E. V., Escudero-Pérez, B., Pillny, M., Ly, M. L., Koundouno, F. R., Bore, J. A., Magassouba, NF., Dahlke, C., Günther, S., Carroll, M. W., Addo, M. M., & Muñoz-Fontela, C. (2020). Ebola virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins. Viruses, 12(9), Article 915. https://doi.org/10.3390/v12090915

@article{7c18190e5f434c6a8c79a2c2427cacb1,

title = "Ebola virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins",

abstract = "The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates.",

keywords = "Antibodies, Ebola virus, Immune memory, VSV, Vaccine",

author = "Till Koch and Monika Rottstegge and Paula Ruibal and Sergio Gomez-Medina and Nelson, {Emily V.} and Beatriz Escudero-P{\'e}rez and Matthias Pillny and Ly, {My Linh} and Koundouno, {Fara Raymond} and Bore, {Joseph Akoi} and N{\textquoteright}Faly Magassouba and Christine Dahlke and Stephan G{\"u}nther and Carroll, {Miles W.} and Addo, {Marylyn M.} and C{\'e}sar Mu{\~n}oz-Fontela",

note = "Publisher Copyright: {\textcopyright} 2020 by the authors. Licensee MDPI, Basel, Switzerland.",

year = "2020",

month = sep,

doi = "10.3390/v12090915",

language = "English",

volume = "12",

journal = "Viruses",

issn = "1999-4915",

publisher = "MDPI",

number = "9",

}

Koch, T, Rottstegge, M, Ruibal, P, Gomez-Medina, S, Nelson, EV, Escudero-Pérez, B, Pillny, M, Ly, ML, Koundouno, FR, Bore, JA, Magassouba, NF, Dahlke, C, Günther, S, Carroll, MW, Addo, MM & Muñoz-Fontela, C 2020, 'Ebola virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins', Viruses, vol. 12, no. 9, 915. https://doi.org/10.3390/v12090915

TY - JOUR

T1 - Ebola virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins

AU - Koch, Till

AU - Rottstegge, Monika

AU - Ruibal, Paula

AU - Gomez-Medina, Sergio

AU - Nelson, Emily V.

AU - Escudero-Pérez, Beatriz

AU - Pillny, Matthias

AU - Ly, My Linh

AU - Koundouno, Fara Raymond

AU - Bore, Joseph Akoi

AU - Magassouba, N’Faly

AU - Dahlke, Christine

AU - Günther, Stephan

AU - Carroll, Miles W.

AU - Addo, Marylyn M.

AU - Muñoz-Fontela, César

PY - 2020/9

Y1 - 2020/9

N2 - The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates.

AB - The last seven years have seen the greatest surge of Ebola virus disease (EVD) cases in equatorial Africa, including the 2013–2016 epidemic in West Africa and the recent epidemics in the Democratic Republic of Congo (DRC). The vaccine clinical trials that took place in West Africa and the DRC, as well as follow-up studies in collaboration with EVD survivor communities, have for the first time allowed researchers to compare immune memory induced by natural infection and vaccination. These comparisons may be relevant to evaluate the putative effectiveness of vaccines and candidate medical countermeasures such as convalescent plasma transfer. In this study, we compared the long-term functionality of anti-EBOV glycoprotein (GP) antibodies from EVD survivors with that from volunteers who received the recombinant vesicular stomatitis virus vectored vaccine (rVSV-ZEBOV) during the Phase I clinical trial in Hamburg. Our study highlights important differences between EBOV vaccination and natural infection and provides a framework for comparison with other vaccine candidates.

KW - Antibodies

KW - Ebola virus

KW - Immune memory

KW - VSV

KW - Vaccine

UR - http://www.scopus.com/inward/record.url?scp=85089794182&partnerID=8YFLogxK

U2 - 10.3390/v12090915

DO - 10.3390/v12090915

M3 - Article

C2 - 32825479

AN - SCOPUS:85089794182

SN - 1999-4915

VL - 12

JO - Viruses

JF - Viruses

IS - 9

M1 - 915

ER -

Ebola virus disease survivors show more efficient antibody immunity than vaccinees despite similar levels of circulating immunoglobulins

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this